Telix to Acquire ITM for $1.65B — a Radiopharma Consolidation Built Around ITM-11, the Drug the FDA Just Rejected

Telix to Acquire ITM for $1.65B — a Radiopharma Consolidation Built Around ITM-11, the Drug the FDA Just Rejected

On September 21, 2026, Australia's Telix Pharmaceuticals announced a strategic agreement to lead a merger with Germany's ITM Isotope Technologies Munich SE — a deal that creates a vertically integrated challenger to Novartis's dominance in radiopharmaceuticals, and whose contingent payments hinge on the regulatory resurrection of ITM-11, the GEP-NET radioligand therapy the FDA rejected on manufacturing grounds just last month (see FDA Rejects ITM’s Radiopharmaceutical ITM-11 Over Manufacturing and Third-Party Facility Deficiencies). STAT's framing was blunt: "Radiopharmaceutical companies merge after one receives surprise FDA rejection.1"

Deal terms (from Telix's announcement):

• US$1.65 billion upfront on a cash-free/debt-free basis: US$1.25B in 105.8M Telix shares (at $11.841, the 30-day VWAP), US$302M of net debt assumed, US$96M of management equity rollover and transaction expenses. Post-close ownership: Telix holders ~76.3%, ITM holders ~23.7%. Subject to Telix shareholder approval at an EGM expected November 2026; closing expected by end of FY2026.
• Up to US$700 million contingent, tied specifically to ITM-11: US$250M in regulatory milestones — US$100M on FDA approval in G1–G2 GEP-NETs no later than December 31, 2027, US$100M for a G2–G3 GEP-NETs indication by end-2030, US$50M for lung NETs by end-2031 — plus up to US$450M on FY2030 net global sales above US$150M.

What Telix is buying: ITM is "the world's leading supplier of therapeutic radioisotopes" (lutetium-177, actinium-225, terbium-161) and "the only producer of globally scaled commercial-grade 177Lu," with a distribution network in 65+ countries, US$273M of 2025 revenue and a 40% CAGR since 2021. ITM-11 (177Lu-edotreotide) completed its Phase 3 COMPETE trial and has a second Phase 3 (COMPOSE) fully enrolled with an interim analysis expected H1 2027 — a direct rival to Novartis's Lutathera. Combined pro forma 2026 revenue is estimated above US$1.3 billion.

Telix CEO Dr. Christian Behrenbruch: "This merger positions Telix at the forefront of the consolidation that is occurring as the industry matures... this combination further expands our late-stage therapeutic pipeline with two completed Phase 3 trials and deepens radioisotope security."

What it means: The August CRL on ITM-11 was a manufacturing/CMC rejection, not an efficacy one² — and Telix is effectively underwriting the fix, paying sellers mostly in stock and reserving the cash milestones for exactly the regulatory outcomes (starting with FDA approval by end-2027) that the CRL put at risk. It also hands Telix the isotope supply chain that both its own pipeline and the broader industry depend on. Analysts framed it as Telix "cornering" the radiopharma value chain against Novartis.